Abscess

Public Advisory - Two lots of cystic fibrosis drug Cayston recalled due to the potential of cracked glass vials

Retrieved on: 
Saturday, March 18, 2023

Health Canada is advising the public that Gilead Sciences Incorporated recalled two lots (032168 and 033357) of the cystic fibrosis drug Cayston (aztreonam) (DIN 02329840) on March 1, 2023 , due to the potential of cracked glass vials in those lots, which may introduce glass particles into the medication.

Key Points: 
  • Health Canada is advising the public that Gilead Sciences Incorporated recalled two lots (032168 and 033357) of the cystic fibrosis drug Cayston (aztreonam) (DIN 02329840) on March 1, 2023 , due to the potential of cracked glass vials in those lots, which may introduce glass particles into the medication.
  • A cracked glass vial could cause potential injury or lead to potential contamination or a reduced dose.
  • Cayston is a prescription antibacterial medicine used for the management of chronic infections in cystic fibrosis patients.
  • The manufacturer has not received any customer complaints in relation to cracked glass vials in the recalled lots, or any other Cayston lots distributed in Canada.

Fine Dental Care in Wayne, NJ Announces Launch of New Website

Retrieved on: 
Thursday, March 16, 2023

WAYNE, N.J., March 16, 2023 /PRNewswire-PRWeb/ -- Fine Dental Care is pleased to announce the launch of its new website at https://www.finedentalcare.com. The website was designed to give visitors easy access to information about services and procedures offered by Fine Dental Care and its affiliated providers. Visitors can also contact the office for appointments or request more information about the practice.

Key Points: 
  • WAYNE, N.J., March 16, 2023 /PRNewswire-PRWeb/ -- Fine Dental Care is pleased to announce the launch of its new website at https://www.finedentalcare.com .
  • The website was designed to give visitors easy access to information about services and procedures offered by Fine Dental Care and its affiliated providers.
  • The new website was designed to bring a simple and easy-to-use experience to site visitors and patients of Fine Dental Care.
  • Fine Dental Care offers a range of dental services, including general dentistry, cosmetic dentistry, implantology, root canal therapy, and more.

Laguna Treatment Hospital Warns of Adulterant Xylazine in Illicit Drug Supply

Retrieved on: 
Tuesday, March 14, 2023

ALISO VIEJO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Laguna Treatment Hospital, a leading provider of substance use and co-occurring mental health treatment, is warning residents about the dangers of xylazine, a veterinary anesthetic appearing in the state’s illicit drug supply.

Key Points: 
  • ALISO VIEJO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Laguna Treatment Hospital, a leading provider of substance use and co-occurring mental health treatment, is warning residents about the dangers of xylazine, a veterinary anesthetic appearing in the state’s illicit drug supply.
  • Illicit xylazine use was reported back In the early 2000s and became a worrying issue in Puerto Rico in the mid-2000s.
  • It wasn’t until 2019 that its presence was felt nationwide when it was primarily used as a fentanyl additive.
  • “Xylazine really has the potential to make this overdose crisis the country’s experiencing significantly worse, and unfortunately, I think that’s what might happen,” said Dr. Gary Mitrevolis, medical director at Laguna Treatment Hospital.

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

Retrieved on: 
Friday, February 10, 2023

Incyte (Nasdaq:INCY) today announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (formerly INCB54707), an oral JAK1 inhibitor, in adult patients with hidradenitis suppurativa (HS).

Key Points: 
  • Incyte (Nasdaq:INCY) today announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (formerly INCB54707), an oral JAK1 inhibitor, in adult patients with hidradenitis suppurativa (HS).
  • These data were presented as an oral presentation (Abstract #258) at the 12th Conference of the European Hidradenitis Suppurativa Foundation, held from February 8-10, 2023, in Florence, Italy.
  • Povorcitinib was generally well tolerated and the safety profile was consistent with previously-reported data.
  • We look forward to continuing to progress the development of povorcitinib through our ongoing Phase 3 trial in patients with moderate-to-severe HS.”
    Additional 52-week efficacy results include:

MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa

Retrieved on: 
Thursday, February 2, 2023

The MIRA trial (M1095-HS-201) is the first global, randomized, double-blind, placebo-controlled trial using Hidradenitis Suppurativa Clinical Response (HiSCR) 75, a higher measure of clinical response, as its primary endpoint.

Key Points: 
  • The MIRA trial (M1095-HS-201) is the first global, randomized, double-blind, placebo-controlled trial using Hidradenitis Suppurativa Clinical Response (HiSCR) 75, a higher measure of clinical response, as its primary endpoint.
  • Sonelokimab (M1095) is a Nanobody® designed to directly target sites of inflammation by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers and to penetrate difficult-to-reach inflamed tissues.
  • Kristian Reich, Founder and Chief Scientific Officer at MoonLake, commented: “The rapid completion of enrollment and randomization for our Phase 2 trial reflects the need for new treatment options and the clinical interest in evaluating the Nanobody® sonelokimab in hidradenitis suppurativa.
  • Sonelokimab is currently being evaluated in a Phase 2 trial ( NCT05640245 ), ‘ARGO’, in patients with active psoriatic arthritis and recruitment is ongoing.

2022 Hidradenitis Suppurativa (HS) Epidemiology Forecast to 2032: The US has the Largest Number of Affected People - ResearchAndMarkets.com

Retrieved on: 
Monday, January 16, 2023

The epidemiology segment also provides the Hidradenitis Suppurativa epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Key Points: 
  • The epidemiology segment also provides the Hidradenitis Suppurativa epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • Among the EU-5 countries, Germany accounted for the highest number of Hidradenitis Suppurativa cases, whereas Spain accounted for the lowest cases in 2021.
  • A detailed review of Hidradenitis Suppurativa epidemiology forecast is included in the report, covering the 7MM drug outreach.
  • The Hidradenitis Suppurativa Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies.

Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials

Retrieved on: 
Wednesday, December 14, 2022

The Phase 1a dose escalation portion of the trial is ongoing; dose level 1 (DL1, 0.05 mg/kg) has been completed with a total of four patients enrolled.

Key Points: 
  • The Phase 1a dose escalation portion of the trial is ongoing; dose level 1 (DL1, 0.05 mg/kg) has been completed with a total of four patients enrolled.
  • All patients were heavily pretreated with multiple prior lines of therapy and included three patients with solid tumors and one patient with cutaneous T-cell lymphoma.
  • Kymera is currently preparing to initiate a Phase 1 clinical trial evaluating the safety, tolerability, PK/PD and clinical activity of KT-253 in adult patients with liquid and solid tumors in 2023.
  • No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy

Retrieved on: 
Thursday, December 8, 2022

Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.

Key Points: 
  • Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.
    CABOMETYX in combination with atezolizumab is not indicated as a treatment for NSCLC.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies.
  • Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients.
  • Discontinue CABOMETYX in patients who develop an acute myocardial infarction or serious arterial or venous thromboembolic events that require medical intervention.

InventHelp Inventors Develop Self Contained Abcess Drainage System (CSK-318)

Retrieved on: 
Friday, December 16, 2022

PITTSBURGH, Dec. 16, 2022 /PRNewswire/ -- "I'm a pediatric surgeon and I thought there could be an improved way to lance an abscess," said one of two inventors, from Myrtle Beach, S.C., "so we invented the SELF CONTAINED ABCESS DRAINAGE SYSTEM.

Key Points: 
  • PITTSBURGH, Dec. 16, 2022 /PRNewswire/ -- "I'm a pediatric surgeon and I thought there could be an improved way to lance an abscess," said one of two inventors, from Myrtle Beach, S.C., "so we invented the SELF CONTAINED ABCESS DRAINAGE SYSTEM.
  • The patent-pending invention provides an improved way to lance an abscess.
  • It also allows for drainage and it could reduce post-operative wound care and the incidence of infection.
  • The original design was submitted to the National sales office of InventHelp.

InventHelp Inventors Develop Self Contained Abcess Drainage System (CSK-318)

Retrieved on: 
Friday, December 2, 2022

PITTSBURGH, Dec. 2, 2022 /PRNewswire/ --"I'm a pediatric surgeon and I thought there could be an improved way to lance an abscess," said one of two inventors, from Myrtle Beach, S.C., "so we invented the SELF CONTAINED ABCESS DRAINAGE SYSTEM.

Key Points: 
  • PITTSBURGH, Dec. 2, 2022 /PRNewswire/ --"I'm a pediatric surgeon and I thought there could be an improved way to lance an abscess," said one of two inventors, from Myrtle Beach, S.C., "so we invented the SELF CONTAINED ABCESS DRAINAGE SYSTEM.
  • The patent-pending invention provides an improved way to lance an abscess.
  • It also allows for drainage and it could reduce post-operative wound care and the incidence of infection.
  • The original design was submitted to the National sales office of InventHelp.